genetic disease News
-
Gene for Brain Connections Linked with Autism
Reuters – March 19, 2008 – Health and Science article featuring Population Diagnostics cofounder Dr. Hatchwell’s discovery of autism gene Contactin 4 (CNTN4) [Journal of Medical Genetics paper]; cites Population Diagnostics is developing early detection tests for autism and other genetic diseases Full story ...
-
AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the 21st Annual Needham Virtual Healthcare Conference at 9:30 a.m. ET on Tuesday, April 12, 2022. A live webcast of the presentation will be available on the investors ...
-
Deep Genomics to Present at the 40 th Annual J.P. Morgan Healthcare Conference
January 6, 2022. Deep Genomics, the leading AI RNA therapeutics company, today announced that its Founder and CEO, Brendan Frey, PhD, FRSC, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 10:00 a.m. EST. The presentation will be available as a live webcast through the J.P. Morgan Healthcare Conference portal. About Deep Genomics Deep Genomics ...
-
Mila Announces Collaboration with Leading AI Therapeutics Company Deep Genomics
Mila, the Quebec Artificial Intelligence Institute, today announced the start of a partnership with Deep Genomics, a leading company in therapeutic artificial intelligence treatments. This collaboration will allow the company to join Mila's community and to take advantage of the recruitment activities offered by the research institute. Deep Genomics uses AI and machine learning to program and ...
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 63,000 shares of the company’s common stock to one new employee as an inducement award under the company’s 2019 Inducement Plan. In ...
-
Deep Genomics Raises $180M in Series C Financing
Company expands AI discovery platform for ‘Programmable’ RNA therapeutics and supports advancement of its portfolio into the clinic Oversubscribed round led by SoftBank Vision Fund 2, with CPP Investments, Fidelity Management & Research Company LLC, Alexandria Venture Investments, Amplitude Ventures, Khosla Ventures, Magnetic Ventures, and True Ventures Deep Genomics, the ...
-
CD Genomics Expands Its Sequencing Portfolio with the Launch of Whole Exome Sequencing
CD Genomics is a world-leading genomics services company that continues to innovate in sequencing solutions for the genomics industry, covering genotyping, library construction, bioinformatics, microarrays, mutagenesis analysis, and more. CD Genomics is pleased to offer whole exome sequencing services, which can help scientists discover disease-related mutation sites more accurately. Exomes are ...
By CD Genomics
-
Minaris will be the commercial manufacturer in Europe for Skysona™, bluebird bio`s gene therapy for CALD
Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry, will be the commercial manufacturer in Europe for SkysonaTM (elivaldogene autotemcel, Lenti-D™), a product of bluebird bio, Inc. Today, the European Commission (EC) has granted marketing authorization for SkysonaTM, the ...
-
Deep Genomics to Participate in Citi PCA - Private Company Digital Health Conference
Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today that its Founder and Chief Executive Officer, Brendan Frey, Ph.D., F.R.S.C., will participate in a panel discussion during the Citi PCA – Private Company Digital Health Conference *VIRTUAL* on May 20, 2021. Details: Session: Artificial Intelligence in Drug Discovery Date and time: Thursday, ...
-
Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder
Camurus (NASDAQ STO: CAMX) today announces that the company’s license partner Rhythm Pharmaceuticals has dosed the first patients in a Phase 3 trial evaluating weekly setmelanotide subcutaneous depot in patients six years of age and older with a rare genetic disease of obesity. “We are pleased with the progress of our collaboration with Rhythm and today’s announcement of the ...
By Camurus AB
-
Population Bio Recognizes World Rare Disease Day 2017 with a Commitment to Provide New Insights into Rare Diseases
Pioneering technology platform rapidly uncovers the genetic causes of unsolved diseases and redefines the understanding of rare and complex genetic diseases. Melville, NY, (February 28, 2017) Population Bio (PB) – a global leader in gene discovery announced, in support of World Rare Disease Day, its continued investment in its CNV Beacon® gene discovery platform which delivers new ...
-
Creative Enzymes Launches Native Porcine Prolidase for Research and Diagnostic Use
As an excellent supplier and manufacturer located in New York, Creative Enzymes has recently launched native porcine prolidase used for research and diagnosis. Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has won a good reputation all over the world Prolidase has an important role in recycling proline and collagen ...
-
CRISPR QC Accepted into EvoNexus - San Diego’s Premier Startup Incubator
On August 12, 2022, EvoNexus, California’s leading non-profit tech incubator, selected CRISPR QC to become a portfolio company. “The right environment and mentorship is critical to the success of any early stage company. As a returning alumnus of the EvoNexus program, I'm thrilled to be bringing CRISPR QC into their portfolio and know just how well they can boost the growth of the ...
By CRISPR QC
-
Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Mammoth Biosciences, a biotech company building the next generation of CRISPR products to cure and detect disease, today announced a new partnership to develop in vivo gene-editing therapies for two genetic diseases using Mammoth’s next-generation CRISPR systems. “We believe our novel ultra-small CRISPR systems have the potential ...
-
Healx pledges $25,000 to AKU Society patient registry campaign
Patient registries play a critical role in the development of treatments for rare diseases – 95% of which are still without an approved therapy today. Knowledge limitations around rare conditions are a huge barrier to treatment development and are compounded by the fact that rare disease patient populations are often small and geographically dispersed. Registries collect information ...
By Healx Ltd.
-
University of Phoenix and HandsOn Network recognize Rickie Santer as a University of Phoenix(TM) volunteer leader award honoree
Rickie Santer, of Levittown, NY has been named a University of Phoenix Volunteer Leader Award Honoree, an award given by HandsOn Network and the University of Phoenix to 10 outstanding volunteer leaders in the nation. These leaders motivate others and are catalysts for change in their communities. The award celebrates the first anniversary of the landmark Edward M. Kennedy Serve America Act, ...
-
RareStone Group & Rhythm Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide) in China
RareStone to seek marketing authorization for IMCIVREE to treat obesity due to biallelic POMC, PCSK1 and LEPR deficiencies and Bardet-Biedl and Alström syndromes in mainland China, Hong Kong and Macau – BOSTON, December 2, 2021 -- RareStone Group, a rare disease focused company aiming to establish the first rare disease ecosystem in China, Rhythm Pharmaceuticals, Inc. (Nasdaq: ...
-
August 2022 is Spinal Muscular Atrophy Awareness Month!
Every year, the month of August is nationally recognized as Spinal Muscular Atrophy (SMA) Awareness Month. This month-long awareness campaign serves as an important time to demonstrate support and help promote awareness for this rare disease affecting lives across the world. WHAT IS SMA? Affecting 4 people in every 100,000 in the U.S., Spinal Muscular Atrophy (SMA) is a genetic, progressive ...
-
Deep Genomics Appoints Jeffrey M. Brown, Ph.D., Vice President of Preclinical Research
Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the appointment of Jeffrey Brown, Ph.D., Vice President, Preclinical Research. Jeffrey will be responsible for advancing programs into IND-enabling studies, overseeing the discipline of experimental biology, and working with the leadership team on scientific and business strategies. Fueled by their AI ...
-
CD Genomics Launches Advanced Whole Exome Sequencing Service, Empowering Genetic Research
CD Genomics, a renowned provider of genomics services, is proud to unveil its cutting-edge Whole Exome Sequencing (WES) service. This offering provides researchers and clinicians with a powerful tool to investigate the exome, shedding light on the intricacies of the human genome and propelling our understanding of genetic diseases. In the era of precision medicine, comprehensive and precise ...
By CD Genomics
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you